Maze Therapeutics (NASDAQ:MAZE) CEO Jason Coloma Sells 3,993 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 3,993 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $26.00, for a total value of $103,818.00. Following the completion of the transaction, the chief executive officer owned 25,930 shares in the company, valued at approximately $674,180. The trade was a 13.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Trading Up 0.7%

NASDAQ MAZE opened at $26.60 on Thursday. The company has a market cap of $1.47 billion, a price-to-earnings ratio of -10.51 and a beta of 2.26. Maze Therapeutics, Inc. has a 52 week low of $9.83 and a 52 week high of $53.65. The business has a 50 day moving average price of $25.66 and a 200-day moving average price of $36.14. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The firm had revenue of $20.00 million during the quarter. As a group, equities analysts expect that Maze Therapeutics, Inc. will post -2.76 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Maze Therapeutics

A number of hedge funds have recently bought and sold shares of MAZE. Royal Bank of Canada grew its stake in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after acquiring an additional 363 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Maze Therapeutics during the fourth quarter valued at about $39,000. Ameritas Investment Partners Inc. boosted its holdings in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Maze Therapeutics during the fourth quarter worth about $43,000. Finally, Russell Investments Group Ltd. grew its position in Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after purchasing an additional 1,725 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Truist Financial dropped their price objective on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, April 14th. BTIG Research restated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, March 25th. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Wedbush raised their price target on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research report on Monday, March 16th. Finally, HC Wainwright lifted their price target on Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.